Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21913 | 0.84 | YTHDC1 (0.47) | PDPK1YTHDC1HTTYTHDF2CYP1A2 | |
| SCHEMBL10918759 | 0.82 | YTHDC1 (0.46) | PDPK1YTHDC1HTTYTHDF2CYP1A2 | |
| SCHEMBL6272986 | 0.82 | YTHDC1 (0.46) | PDPK1YTHDC1HTTYTHDF2CYP1A2 | |
| SCHEMBL30677338 | 0.78 | PDPK1 (0.33) | PDPK1HTTCYP1A2HIF1AEGFR | |
| SCHEMBL2116843 | 0.78 | PDPK1 (0.33) | PDPK1HTTCYP1A2HIF1AEGFR | |
| SCHEMBL11591791 | 0.78 | HTT (0.33) | HTTCYP1A2HIF1AEGFRMEN1 | |
| SCHEMBL21828774 | 0.78 | LMNA (0.48) | CYP1A2HIF1AMEN1RAB9AKMT2A | |
| SCHEMBL9116343 | 0.76 | HTT (0.32) | HTTCYP1A2HIF1AEGFRCSNK2A1 | |
| SCHEMBL22892194 | 0.76 | CSNK2A1 (0.33) | PDPK1YTHDC1HTTYTHDF2CYP1A2 | |
| SCHEMBL4242949 | 0.76 | EGFR (0.33) | HTTCYP1A2HIF1AEGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-20100272721-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100113294-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| CN-101681396-A | Glucoprotein product that limits and associated method | MOMENTA PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2137655-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | Momenta Pharmaceuticals, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080292622-A1 | METHODS OF EVALUATING PATIENTS | BIOGEN IDEC MA INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080279853-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008128230-A1 | REFERENCE GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128227-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2006138219-A2 | METHODS OF DIAGNOSIS / PROGNOSIS OF INFLAMMATORY CONDITIONS | BIOGEN IDEC MA INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006130429-A2 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | PDPK1 698/4885YTHDC1 4317/4885HTT 2515/4885 |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | PDPK1 1256/4885YTHDC1 4346/4885HTT 1980/4885 |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | PDPK1 4125/4885YTHDC1 2905/4885HTT 541/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885YTHDC1 1740/4885HTT 4166/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | PDPK1 4125/4885YTHDC1 2905/4885HTT 541/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885YTHDC1 1740/4885HTT 4166/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PDPK1 3892/4885YTHDC1 1945/4885HTT 3724/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3738/4885YTHDC1 1740/4885HTT 4166/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PDPK1 3892/4885YTHDC1 1945/4885HTT 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.